How Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis?
Klodeta Kura(MSD (UK) Limited (United Kingdom)), Luc E. Coffeng(Erasmus MC), Wilma A. Stolk(Erasmus MC), Roy M. Anderson(NIHR Imperial Biomedical Research Centre), Benjamin Collyer(Imperial College London), Katherine Gass(The Task Force for Global Health), Peter J. Diggle(Lancaster University), Sake J. de Vlas(Erasmus MC), Marı́a-Gloria Basáñez(Imperial College London), Jonathan D. King(World Health Organization), T. Déirdre Hollingsworth(University of Oxford), Matthew Graham(University of Oxford), Alison Krentel(Bruyère)
Cited by 14
Related Papers
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
|The Lancet|2012|9k
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
|The Lancet|2012|8.4k
Infectious Diseases of Humans
|Unknown|1991|6k
Population biology of infectious diseases: Part I
|Nature|1979|3.2k
Regulation and Stability of Host-Parasite Population Interactions: I. Regulatory Processes
|Journal of Animal Ecology|1978|1.8k